Danaher Corporation publiziert öffentliches Kaufangebot für alle sich im Publikum befindenden Nobel Biocare-Aktien

Danaher Corporation hat heute das am 15. September 2014 angekündigte öffentliche Kaufangebot für sämtliche sich im Publikum befindlichen Namenaktien von Nobel Biocare Holding AG mit einem Nennwert von je CHF 0.40 veröffentlicht. Der Angebotspreis beträgt CHF 17.10 in bar pro Namenaktie.

Der Verwaltungsrat von Nobel Biocare hat am 14. September 2014 einstimmig (mit einem Mitglied im Ausstand) beschlossen, den Aktionären das Angebot von Danaher zur Annahme zu empfehlen. Der Verwaltungsrat von Nobel Biocare hat das Angebot eingehend geprüft und kommt zum Schluss, dass das Bargeld-Angebot im besten Interesse von Nobel Biocare, deren Aktionären, Mitarbeitenden, Kunden und Lieferanten ist. Der Bericht des Verwaltungsrats zum Angebot wurde heute im Angebotsprospekt von Danaher veröffentlicht.

N+1 Swiss Capital AG hat zuhanden des Verwaltungsrats von Nobel Biocare eine Fairness Opinion erstellt und darin bestätigt, dass der Angebotspreis von CHF 17.10 in bar pro Namenaktie in finanzieller Hinsicht fair und angemessen ist.

Die Übernahmekommission hat in Ihrer Verfügung vom 29. September 2014 entschieden, dass das Angebot von Danaher den gesetzlichen Bestimmungen über öffentliche Kaufangebote entspricht.

Die Fairness Opinion kann bei Nobel Biocare (Tel.: +41 (0)43 211 42 30, E-Mail: investor.relations@nobelbiocare.com) bezogen respektive auf http://corporate.nobelbiocare.com/en/investors/offer_restrictions/default.aspx abgerufen werden. Der Angebotsprospekt samt Bericht des Verwaltungsrates kann bei Credit Suisse AG, Zürich (Tel.: +41 (0)44 333 43 85; E-Mail: equity.prospectus@credit-suisse.com) bezogen respektive auf http://phx.corporate-ir.net/phoenix.zhtml?c=82105&p=irol-irhome abgerufen werden.

Indikativer, weiterer Zeitplan der Transaktion

Kontaktinformation:

Finanzkalender:

Danaher Corporation (NYSE: DHR) is a global science and technology innovator committed to helping its customers solve complex challenges and improving quality of life around the world. Its family of world class brands have unparalleled leadership positions in some of the most demanding and attractive industries, including health care, environmental and communications. The company's globally diverse team of 66,000 associates is united by a common culture and operating system, the Danaher Business System. In 2013, Danaher generated $19.1 billion in revenue and its market capitalization exceeded $50 billion. For more information please visit www.danaher.com.

Disclaimer

This media release contains forward-looking statements based on beliefs of Nobel Biocare's management. When used in this media release, words such as "anticipate", "believe", "estimate", "expect", "intend", "plan" and "project" are intended to identify forward-looking statements. They may involve risks and uncertainties, including technological advances in the medical field, product demand and market acceptance, the effect of economic conditions, the impact of competitive products and pricing, foreign currency exchange rates and other risks. These forward-looking statements reflect the views of Nobel Biocare as of the date made with respect to future events and are subject to risks and uncertainties. All of these forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results or experience could differ materially from the forward-looking statements. Nobel Biocare disclaims any intention or obligation to update these forward-looking statements.

Angebotsrestriktionen

Das öffentliche Kaufangebot wird weder direkt noch indirekt in einem Land oder einer Rechtsordnung unterbreitet, in welchem/welcher ein solches Angebot widerrechtlich wäre, oder in welchem/welcher es in anderer Weise anwendbares Recht oder anwendbare Bestimmungen verletzen würde, oder welches/welche von Danaher oder einer ihrer Tochtergesellschaften irgendeine Änderung der Bestimmungen oder Bedingungen des Angebots, ein zusätzliches Gesuch an staatliche oder regulatorische Behörden oder zusätzliche Handlungen in Bezug auf das Angebot erfordern würde. Es ist nicht beabsichtigt, das Angebot auf ein solches Land oder eine solche Rechtsordnung auszudehnen. Dokumente, die im Zusammenhang mit dem Angebot stehen, dürfen weder in solchen Ländern oder Rechtsordnungen verteilt, noch in solche Länder oder Rechtsordnungen gesandt werden. Solche Dokumente dürfen nicht zum Zwecke der Werbung für Käufe von Beteiligungsrechten an Nobel Biocare durch juristische oder natürliche Personen verwendet werden, die in solchen Ländern oder Rechtsordnungen wohnhaft oder inkorporiert sind.

Notice to U.S. Holders

The Offer is being made for the registered shares of Nobel Biocare, a Swiss company, and is subject to Swiss disclosure requirements, which are different from those of the United States (U.S.). U.S. holders of Nobel Biocare shares are encouraged to consult with their own Swiss advisors in connection with the Offer.

The receipt of cash pursuant to the Offer by a U.S. holder of Nobel Biocare shares may be a taxable transaction for U.S. federal income tax purposes and under applicable U.S. state and local, as well as foreign and other tax laws. Each shareholder of Nobel Biocare is urged to consult his independent professional advisor immediately regarding the tax consequences of acceptance of the Offer.

According to the laws of Switzerland, Nobel Biocare shares tendered into the Offer may generally not be withdrawn after they are tendered except under certain circumstances, in particular in case a competing offer for the Nobel Biocare shares is launched.

It may be difficult for U.S. holders to enforce their rights and any claim arising out of U.S. federal securities laws, since Nobel Biocare is located in a non-U.S. jurisdiction, and some or all of its or Danaher's officers or directors may be residents of a non-U.S. jurisdiction. U.S. holders may not be able to sue a non-U.S. company or its officers or directors in a non-U.S. court for violations of the U.S. securities laws. Further, it may be difficult to compel a non-U.S. company and its affiliates to subject themselves to a U.S. court's judgment.

In accordance with the laws of Switzerland and subject to applicable regulatory requirements, Danaher, its subsidiaries or any of its or their nominees or brokers (acting as agents) may from time to time make certain purchases of, or arrangements to purchase, Nobel Biocare shares outside the U.S., other than pursuant to the Offer. These purchases, or arrangements to purchase, may occur either in the open market at prevailing prices or in private transactions at negotiated prices and shall comply with applicable laws and regulations in Switzerland and applicable U.S. securities laws. Any information about such purchases or arrangements to purchase will be publicly disclosed in the U.S. on Danaher's website to the extent that such information is made public in accordance with the applicable laws and regulations of Switzerland.

United Kingdom

This communication is directed only at persons in the United Kingdom (U.K.) who (i) have professional experience in matters relating to investments, (ii) are persons falling within article 49(2)(a) to (d) («high net worth companies, unincorporated associations, etc.») of The Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 or (iii) to whom it may otherwise lawfully be communicated (all such persons together being referred to as «relevant persons»). This communication must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this communication relates is available only to relevant persons and will be engaged in only with relevant persons.

Australia and Japan

The Offer is not addressed to shareholders of Nobel Biocare whose place of residence, seat or habitual abode is in Australia or Japan, and such shareholders may not accept the Offer.